Trial · NCT01214421
Adverse events980
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
161 to 180 of 980
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Cough | Respiratory, thoracic and mediastinal disorders | Tolvaptan (From Study 156-04-251: Tolvaptan, Early Treated) | 42 | 557 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Tolvaptan (From Study 156-04-251: Placebo, Delayed Treated) | 23 | 314 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Tolvaptan (From Other Studies: Tolvaptan, Early Treated) | 10 | 181 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Tolvaptan (From Other Studies: Placebo, Delayed Treated) | 0 | 31 | |
| other | Dry Skin | Skin and subcutaneous tissue disorders | Tolvaptan (From Study 156-04-251: Tolvaptan, Early Treated) | 7 | 557 | |
| other | Dry Skin | Skin and subcutaneous tissue disorders | Tolvaptan (From Study 156-04-251: Placebo, Delayed Treated) | 12 | 314 | |
| other | Dry Skin | Skin and subcutaneous tissue disorders | Tolvaptan (From Other Studies: Tolvaptan, Early Treated) | 7 | 181 | |
| other | Dry Skin | Skin and subcutaneous tissue disorders | Tolvaptan (From Other Studies: Placebo, Delayed Treated) | 3 | 31 | |
| other | Hypertension | Vascular disorders | Tolvaptan (From Study 156-04-251: Tolvaptan, Early Treated) | 160 | 557 | |
| other | Hypertension | Vascular disorders | Tolvaptan (From Study 156-04-251: Placebo, Delayed Treated) | 82 | 314 | |
| other | Hypertension | Vascular disorders | Tolvaptan (From Other Studies: Tolvaptan, Early Treated) | 42 | 181 | |
| other | Hypertension | Vascular disorders | Tolvaptan (From Other Studies: Placebo, Delayed Treated) | 2 | 31 | |
| serious | Anaemia | Blood and lymphatic system disorders | Tolvaptan (From Study 156-04-251: Tolvaptan, Early Treated) | 2 | 557 | |
| serious | Anaemia | Blood and lymphatic system disorders | Tolvaptan (From Study 156-04-251: Placebo, Delayed Treated) | 1 | 314 | |
| serious | Anaemia | Blood and lymphatic system disorders | Tolvaptan (From Other Studies: Tolvaptan, Early Treated) | 1 | 181 | |
| serious | Anaemia | Blood and lymphatic system disorders | Tolvaptan (From Other Studies: Placebo, Delayed Treated) | 0 | 31 | |
| serious | Thrombocytopenia | Blood and lymphatic system disorders | Tolvaptan (From Study 156-04-251: Tolvaptan, Early Treated) | 0 | 557 | |
| serious | Thrombocytopenia | Blood and lymphatic system disorders | Tolvaptan (From Study 156-04-251: Placebo, Delayed Treated) | 0 | 314 | |
| serious | Thrombocytopenia | Blood and lymphatic system disorders | Tolvaptan (From Other Studies: Tolvaptan, Early Treated) | 1 | 181 | |
| serious | Thrombocytopenia | Blood and lymphatic system disorders | Tolvaptan (From Other Studies: Placebo, Delayed Treated) | 0 | 31 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01214421/events?page=9